Literature DB >> 33994723

Molecular Biology in the Breast Clinics-Current status and future perspectives.

Vani Parmar1, Nita S Nair2, Purvi Thakkar2, Garvit Chitkara2.   

Abstract

Breast cancer is no longer considered a single disease, and with better understanding of cancer biology, its management has evolved over the years, into a complex individualized use of therapeutics based on variable expressions of predictive and prognostic factors. With the advent of molecular and genetic research, the complexity and diversity of breast cancer cells and their ability to survive and develop resistance to treatment strategies became more evident. At the same time, targeted therapies evolved, as specific targets were discovered such as HER2 receptor, and androgen receptor. More recent is the development of immunotherapy which aims at strengthening the host immune system to identify and kill the tumor cells. In breast cancer treatment, use of molecular tests has been a target of controversies, due to their high costs and inaccessibility in limited resource situations. Research in breast cancer is also proceeding at a rapid pace, but it is important to remember that breast cancer continues to be a complex interplay of alterations at molecular and genetic level, with the variability in expressions at protein level leading to difference in behavior and responses to treatment and overall outcome. In the succeeding paragraphs, we will try to review the available evidence in literature and attempt to understand the molecular complexity of breast cancer in order to simplify the art of treating the disease and improving outcomes. © Indian Association of Surgical Oncology 2019.

Entities:  

Keywords:  Breast cancer; Molecular biology; Outcomes; Prediction

Year:  2019        PMID: 33994723      PMCID: PMC8119514          DOI: 10.1007/s13193-019-00954-1

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  120 in total

1.  The evolution of paradigms for the management of breast cancer: a personal perspective.

Authors:  B Fisher
Journal:  Cancer Res       Date:  1992-05-01       Impact factor: 12.701

2.  A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer.

Authors:  Michele De Laurentiis; Grazia Arpino; Erminia Massarelli; Angela Ruggiero; Chiara Carlomagno; Fortunato Ciardiello; Giampaolo Tortora; Diego D'Agostino; Francesca Caputo; Giuseppe Cancello; Emilia Montagna; Luca Malorni; Luigia Zinno; Rossella Lauria; Angelo Raffaele Bianco; Sabino De Placido
Journal:  Clin Cancer Res       Date:  2005-07-01       Impact factor: 12.531

3.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

Authors:  Soonmyung Paik; Steven Shak; Gong Tang; Chungyeul Kim; Joffre Baker; Maureen Cronin; Frederick L Baehner; Michael G Walker; Drew Watson; Taesung Park; William Hiller; Edwin R Fisher; D Lawrence Wickerham; John Bryant; Norman Wolmark
Journal:  N Engl J Med       Date:  2004-12-10       Impact factor: 91.245

4.  Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.

Authors:  Minna Tanner; Jorma Isola; Tom Wiklund; Björn Erikstein; Pirkko Kellokumpu-Lehtinen; Per Malmström; Nils Wilking; Jonas Nilsson; Jonas Bergh
Journal:  J Clin Oncol       Date:  2006-05-08       Impact factor: 44.544

5.  Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer.

Authors:  Roman Rouzier; Radhika Rajan; Peter Wagner; Kenneth R Hess; David L Gold; James Stec; Mark Ayers; Jeffrey S Ross; Peter Zhang; Thomas A Buchholz; Henry Kuerer; Marjorie Green; Banu Arun; Gabriel N Hortobagyi; W Fraser Symmans; Lajos Pusztai
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-24       Impact factor: 11.205

Review 6.  Triple-negative breast cancer: role of antiangiogenic agents.

Authors:  Sally Greenberg; Hope S Rugo
Journal:  Cancer J       Date:  2010 Jan-Feb       Impact factor: 3.360

7.  Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.

Authors:  Tomasz Byrski; Jacek Gronwald; Tomasz Huzarski; Ewa Grzybowska; Magdalena Budryk; Malgorzata Stawicka; Tomasz Mierzwa; Marek Szwiec; Rafal Wisniowski; Monika Siolek; Rebecca Dent; Jan Lubinski; Steven Narod
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

8.  Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.

Authors:  Marianne Kyndi; Flemming B Sørensen; Helle Knudsen; Marie Overgaard; Hanne Melgaard Nielsen; Jens Overgaard
Journal:  J Clin Oncol       Date:  2008-02-19       Impact factor: 44.544

Review 9.  Combining trastuzumab (Herceptin) with hormonal therapy in breast cancer: what can be expected and why?

Authors:  A Jones
Journal:  Ann Oncol       Date:  2003-12       Impact factor: 32.976

10.  Androgen receptor positive triple negative breast cancer: Clinicopathologic, prognostic, and predictive features.

Authors:  Kristine Astvatsaturyan; Yong Yue; Ann E Walts; Shikha Bose
Journal:  PLoS One       Date:  2018-06-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.